At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Abatacept +1 moredrug
Likely dose
Abatacept 125mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Treating Interstitial Lung Disease Associated With the Anti-synthetase Syndrome
In Brief
A Phase 2 clinical trial evaluating Abatacept and Placebo for Myositis and Interstitial Lung Disease. Completed, enrolled 20 participants across 5 sites.
Detailed Summary
A randomized, controlled pilot trial to evaluate the efficacy and safety of subcutaneous Abatacept in treating interstitial lung disease associated with the anti-synthetase syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyositis, Interstitial Lung Disease
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJul 2017
Enrollment StartJan 2018
Primary CompletionMay 2022
Study CompletionJul 2023
TodayJul 2026
First PostedJul 12, 2017
Enrollment StartJan 1, 2018
Primary CompletionMay 30, 2022
Study CompletionJul 30, 2023
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 9.0 years ago
Interventions
Abataceptdrug
Abatacept 125mg subcutaneous weekly
Placeboother
Placebo